GlassScriptPhysician profile
Oswaldo S Sandoval
NPI 1861435760
$4,653.39
in general payments reported to CMS, 2019-2025
34 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $254 · 2021: $630 · 2022: $509 · 2023: $786 · 2024: $1,151 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472 · Long Term Medical Supply Or Device Loan: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.09 |
| Long Term Medical Supply Or Device Loan | $364.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.34 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $512.14 | 2019-2025 | |
| Cashflow Solutions, LLC | $364.50 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Astrazeneca Pharmaceuticals LP | $299.08 | 2020-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $291.42 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $291.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $271.65 | 2022-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $217.20 | 2019-2024 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.54 | 2020-2024 | Jardiance |
| Hologic Sales and Service, LLC | $197.92 | 2024 | Aptima, Thinprep 2000 Processor |
| Cequr Corporation | $188.66 | 2024-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $170.27 | 2024-2025 | |
| Glaukos Corporation | $135.21 | 2025 | |
| Abbott Laboratories | $109.27 | 2019-2024 | Freestyle Libre, Proclaim |
| Janssen Pharmaceuticals, INC | $83.13 | 2019-2024 | Xarelto |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.68 | 2021-2022 | |
| Lundbeck LLC | $61.46 | 2024-2025 | Rexulti |
| Corcept Therapeutics | $59.22 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $48.42 | 2024-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $48.12 | 2022 | |
| Dexcom, INC. | $46.06 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $45.25 | 2024 | Voquezna |
| Allergan, INC. | $42.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.02 | 2024 | |
| Daiichi Sankyo INC. | $24.77 | 2024 | Injectafer |
| Amarin Pharma, INC. | $23.02 | 2021 | |
| Radius Health, INC. | $20.00 | 2019 | |
| Tactile Systems Technology INC | $19.84 | 2023 | Entre Plus, Flexitouch Plus |
| Philips North America LLC | $16.28 | 2022 | |
| Astellas Pharma US INC | $15.97 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.61 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.58 | 2023 | Rytary |
| Phadia US INC. | $14.27 | 2023 | Immunocap |
| Hikma Pharmaceuticals USA | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oswaldo Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.